As part of our commitment to keeping you informed, we’re thrilled to announce that Bina Therapeutics has established its master cell bank for development! Thanks to the generosity and relentless support of our collaborative partners, the preclinical validation of TRAABA24 can now begin. 

Pseudomyxoma Peritonei (PMP) is an ultra-rare disease, presenting significant challenges in obtaining patient-derived cell cultures essential for advancing research. The scarcity of these cultures limits the ability of scientists to conduct vital assessments, including preclinical testing and mechanistic studies, which are crucial for understanding the disease’s progression and evaluating potential therapeutic interventions. 

The data so far has looked great however, there is still much work to be done. We look forward to reporting back to you over the coming weeks as we continue with steadfast efforts and focused determination to achieve our goals.